Lp(a) Lipoprotein, Vascular Disease, and Mortality in the Elderly

New England Journal of Medicine

Volumn 349, Issue 22, 2003, Pages 2108-2115

  Ariyo, Abraham A ^a,b,e   Thach, Chau ^c   Tracy, Russell ^d  

^a Ctr for Cardiovasc Dis Prevention   (United States)

^b JOHNS HOPKINS HOSPITAL   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d UNIVERSITY OF VERMONT   (United States)

^e HeartMasters   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; ESTROGEN; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

AGE; AGED; ARTERY DIAMETER; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; CAROTID ARTERY; CAUSE OF DEATH; CHOLESTEROL BLOOD LEVEL; COMMUNITY CARE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DEATH; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; ELDERLY CARE; FEMALE; GENDER; HUMAN; HYPERTENSION; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOMES RESEARCH; PRIORITY JOURNAL; SMOKING; STATISTICAL SIGNIFICANCE; STROKE; SYSTOLIC BLOOD PRESSURE; THICKNESS; TRIACYLGLYCEROL BLOOD LEVEL; UNITED STATES; VASCULAR DISEASE;

AGED; CEREBROVASCULAR ACCIDENT; CORONARY DISEASE; FEMALE; HUMANS; INCIDENCE; LIPOPROTEIN(A); MALE; MORTALITY; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK FACTORS; SEX FACTORS; SURVIVAL ANALYSIS; UNITED STATES; VASCULAR DISEASES;

EID: 0345283207     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMoa001066     Document Type: Article

References (36)

1. Fried LP, Borhani NO, Enright P, et al. The Cardiovascular Health Study: design and rationale. Ann Epidemiol 1991;3:263-76.
2. Kannel WB, Vokonas PS. Primary risk factors for coronary heart disease in the elderly: the Framingham Study. In: Wenger NK, Furberg CD, Pitt E, eds. Coronary heart disease in the elderly. New York: Elsevier; 1986: 60-95.
3. Gaubatz JW, Heideman C, Gotto AM Jr, Morrisett JD, Dahlen GH. Human plasma lipoprotein [a]: structural properties. J Biol Chem 1983;258:4582-9.
4. Loscalzo J. Lipoprotein (a): a unique risk factor for atherothrombotic disease. Arteriosclerosis 1990;10:672-9.
5. Ariyo AA, Hennekens CH, Stampfer MJ, Ridker PM, Lipoprotein (a), lipids, aspirin, and risk of myocardial infarction in the Physicians' Health Study. J Cardiovasc Risk 1998;5:273-8.
6. Ridker PM, Hennekens CH, Stampfer MJ. A prospective study of lipoprotein(a) and the risk of myocardial infarction. JAMA 1993;270:2195-9.
7. Cambillau M, Simon A, Amar J, et al. Serum Lp(a) as a discriminant marker of early atherosclerotic plaque at three extracoronary sites in hypercholesterolemic men. Arterioscler Thromb 1992;12:1346-52.
8. Cantin B, Gagnon F, Moorjani S, et al. Is lipoprotein(a) an independent risk factor for ischemic heart disease in men? The Quebec Cardiovascular Study. J Am Coll Cardiol 1998;31:519-25.
9. Schaefer EJ, Lamon-Fava S, Jenner JL, et al. Lipoprotein(a) levels and risk of coronary heart disease in men: the Lipid Research Clinics Coronary Primary Prevention Trial. JAMA 1994;271:999-1003.
10. Bostom AG, Cupples LA, Jenner JL, et al. Elevated plasma lipoprotein(a) and coronary heart disease in men aged 55 years and younger: a prospective study. JAMA 1996; 276:544-8.
11. Assmann G, Schulte H, von Eckardstein A. Hypertriglyceridemia and elevated lipoprotein(a) are risk factors for major coronary events in middle-aged men. Am J Cardiol 1996;77:1179-84.
12. Bostom AG, Gagnon DR, Cupples LA, et al. A prospective investigation of elevated lipoprotein (a) detected by electrophoresis and cardiovascular disease in women: the Framingham Heart Study. Circulation 1994; 90:1688-95.
13. Klausen IC, Sjol A, Hansen PS, et al. Apolipoprotein(a) isoforms and coronary heart disease in men: a nested case-control study. Atherosclerosis 1997;132:77-84.
14. Dahlen GH, Weinehall L, Stenlund H, et al. Lipoprotein(a) and cholesterol levels act synergistically and apolipoprotein A-I is protective for the incidence of primary acute myocardial infarction in middle-aged males: an incident case-control study from Sweden. J Intern Med 1998;244:425-30.
15. Nguyen TT, Bllefson RD, Hodge DO, Bailey KR, Kottke TE, Abu-Lebdeh HS. Predictive value of electrophoretically detected lipoprotein(a) for coronary heart disease and cerebrovascular disease in a community-based cohort of 9936 men and women. Circulation 1997;96:1390-7.
16. Wild SH, Fortmann SP, Marcovina SM. A prospective case-control study of lipoprotein(a) levels and Apo(a) size and risk of coronary heart disease in Stanford Five-City Project participants. Arterioscler Thromb Vase Biol 1997;17:239-45. [Erratum, Arterioscler Thromb Vasc Biol 1997;17:1010.]
17. Wild SH, Fortmann SP, Marcovina SM. A prospective case-control study of lipoprotein(a) levels and Apo(a) size and risk of coronary heart disease in Stanford Five-City Project participants. Arterioscler Thromb Vase Biol 1997;17:239-45. [Erratum, Arterioscler Thromb Vasc Biol 1997;17:1010.]
18. Coleman MP, Key TJA, Wang DY, et al. A prospective study of obesity, lipids, apolipoproteins and ischaemic heart disease in women. Atherosclerosis 1992;92:177-85.
19. Craig WY, Neveux LM, Palomaki GE, Cleveland MM, Haddow JE, Lipoprotein(a) as a risk factor for ischemic heart disease: metaanalysis of prospective studies. Clin Chem 1998;44:2301-6.
20. Sunayama S, Daida H, Mokuno H, et al. Lack of increased coronary atherosclerotic risk due to elevated lipoprotein(a) in women ≥55 years of age. Circulation 1996;94:1263-8.
21. Tell GS, Fried LP, Hermanson B, Manolio TA, Newman AB, Borhani NO. Recruitment of adults 65 years and older as participants in the Cardiovascular Health Study. Ann Epidemiol 1993;3:358-66.
22. Ives GD, Fitzpatrick AL, Bild DE, et al. Surveillance and ascertainment of cardiovascular events: the Cardiovascular Health Study. Ann Epidemiol 1995;5:278-85.
23. Department of Health and Human Services. The international classification of diseases, 9th rev., clinical modification: ICD-9-CM. Vol. 1. Diseases: tabular list Washington, D.C.: Government Printing Office, 1980. (DHHS publication no. (PHS) 80-1260.)
24. Wong WL, Eaton DL, Berloui A, Fendly B, Hass PE. A monoclonal-antibody-based enzyme-linked immunosorbent assay of lipoprotein(a). Clin Chem 1990;36:192-7.
25. Kalbfleisch JD, Prentice RL. The statistical analysis of failure time data. New York: John Wiley, 1980.
26. Cox DR. Regression models and life-tables. J R Stat Soc [B] 1972;34:187-202.
27. SAS/Windows system, release 6.12. Cary, N.C.: SAS Institute, 1996.
28. S-PLUS/Windows system, release 4.5. Seattle: MathSoft, 1998.
29. Kario K, Matsuo T, Imiya M, et al. Close relation between lipoprotein (a) levels and atherothrombotic disease in Japanese subjects >75 years of age. Am J Cardiol 1994;73: 1187-90.
30. Kario K, Matsuo T, Kobayashi H, Asada R, Matsuo M. 'Silent' cerebral infarction is associated with hypercoagulability, endothelial cell damage, and high Lp(a) levels in elderly Japanese. Arterioscler Thromb Vasc Biol 1996;16:734-41.
31. Zenker G, Koltringer P, Bone G, Niederkorn K, Pfeiffer K, Jurger G. Lipoprotein(a) as a strong indicator for cerebrovascular disease. Stroke 1986;17:942-5.
32. Shintani S, Kikuchi S, Hamaguchi H, Shiigai T. High serum lipoprotein(a) levels are an independent risk factor for cerebral infarction. Stroke 1993;24:965-9.
33. Ridker PM, Stampfer MJ, Hennekens CH. Plasma concentration of lipoprotein(a) and the risk of future stroke. JAMA 1995; 273:1269-73.
34. Schlaich MP, John S, Langenfeld MR, Lackner KJ, Schmitz G, Schmieder RE. Does lipoprotein(a) impair endothelial function? J Am Coll Cardiol 1998;31:359-65.
35. Dangas G, Mehran R, Harpel PC, et al. Lipoprotein(a) and inflammation in human coronary atheroma: association with the severity of clinical presentation. J Am Coll Cardiol 1998;32:2035-42.
36. Spencer G. Projections of the population of the United States by age, sex, and race: 1988-2080. Current population reports, population estimates and projections. Series P-25. No. 1018. Washington, D.C.: Bureau of the Census, 1989.